Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion.

Nadine Platet, Anne-Marie Cathiard, Michel Gleizes, Marcel Garcia

To cite this version:


HAL Id: inserm-00144757
http://www.hal.inserm.fr/inserm-00144757
Submitted on 7 May 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion

Nadine Platet, Anne Marie Cathiard, Michel Gleizes, Marcel Garcia

Institut National de la Santé et de la Recherche Médicale, INSERM Unité 540, Molecular and Cellular Endocrinology of Cancers and University Montpellier I, 60 rue de Navacelles, 34090 Montpellier Cedex, France

Abstract

Estrogens play an important role in regulating the growth and differentiation of normal, premalignant and malignant cell types, especially breast epithelial cells, through interaction with two nuclear estrogen receptors (ER\(\alpha\) and ER\(\beta\)). In this review, we present a brief overview of the actions of estrogens in the different steps of breast carcinogenesis, including cancer progression to metastasis, and of their clinical consequences in the prevention, prognosis and treatment of the disease. The requirement of estrogen receptors, mainly of the alpha subtype, in normal mammary gland differentiation and growth has been evidenced by estrogen receptor deficiency in animals. The promotion of breast cancer carcinogenesis by prolonged exposure to estrogens is well-documented and this has logically led to the use of antiestrogens as potentially chemopreventive agents. In breast cancer progression, however, the exact roles of estrogen receptors have been less well established but they may possibly be dual. Estrogens are mitogenic in ER-positive cells and antiestrogens are an efficient adjuvant therapy for these tumors. On the other hand, the fact that estrogens and their receptors protect against cancer cell invasiveness through distinct mechanisms in experimental models may explain why the presence of ER is associated with well-differentiated and less invasive tumors.
1. Introduction
2. Expression of estrogen receptors in normal, premalignant and malignant mammary tissues
   2.1. Normal mammary gland and premalignant lesions
   2.2. Invasive breast carcinoma: ERs as prognostic markers of primary breast cancers
      2.2.1. ERα is associated with a favorable prognosis in primary breast cancers
      2.2.2. Expression of estrogen receptors beta
      2.2.3. Expression of receptor splicing variants
3. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion
   3.1. Estrogens increased ER-positive breast cancer cell growth
      3.1.1. Direct evidence of the mitogenic effect of estrogens
      3.1.2. Involved mechanisms?
   3.2. Are the anti-invasive effects mediated by estrogen receptors responsible for their association with a favorable prognosis of breast cancers?
      3.2.1. Clinical data supporting the hypothesis that estrogens prevent invasion
      3.2.2. Estrogen receptors inhibit invasion through two distinct mechanisms in the presence or absence of hormone
         3.2.2.1. Estrogens inhibit invasion via ERE-regulated genes
         3.2.2.2. Estrogen receptors inhibit invasion independently of ligand binding: involvement of protein-protein interactions
   3.3. Role of estrogen receptor variants in cancer progression?
      3.3.1. Splicing variants of ER alpha and beta
      3.3.2. Mutants with point mutation
4. Antiestrogen approaches for breast cancer therapy and prevention
   4.1. Tamoxifen and other adjuvant therapies of breast cancer
   4.2. Aromatase inhibitors
   4.3. Second therapy for antiestrogen-resistant tumors
   4.4. Implication of estrogens in breast cancer carcinogenesis and the use of antiestrogens as cancer chemopreventive agents
      4.4.1. Tamoxifen, the first chemopreventive SERM in high-risk pre- and postmenopausal women
      4.4.2. Raloxifene and tamoxifen comparison
5. Conclusions
6. Reviewers
References
Vitae
1. Introduction

Breast cancer is one of the most common forms of cancer observed in women. Endogenous estrogens are thought to play a major role in its development and estrogen receptor blockers are important drugs in its treatment [1-3]. It has been shown that longer exposures to estrogens result in an increased risk for breast cancer [4]. Estrogens have effects on many organ systems, beyond the reproductive system, in both females and males. Breast tissue is particularly dependent on circulating estrogens since there is no breast development in aromatase-deficient women and estrogen therapy of these patients leads to normal pre- and postpubertal breast development.

Estrogen effects are exerted through two types of specific receptor: estrogen receptor alpha (ERα) and beta (ERβ) [5-7]. These nuclear receptors are ligand-dependent transcription factors that mediate the biological effects of estrogens and antiestrogens (Figure 1).

Estrogen receptors act mainly by regulating the expression of target genes whose promoters contain specific sequences called estrogen-responsive element (ERE). After ERE-binding of ligand-bound ER dimers, modulation of transcription occurs via interaction with coactivators or corepressors. All together, these complexes play an important role in the recruitment of transcriptional machinery, the modulation of chromatin structure, and then in the regulation of ER target-gene expression [9]. The ER conformation differs with the type of ligand, and there is a marked difference in the topology of the ER surface between agonist- and antagonist-bound receptors [10-12]. Moreover, studies conducted with synthetic antiestrogens, such as tamoxifen, have shown that the agonist/antagonist profile of a ligand varies with the tissue and the target gene considered. This led to the term of selective estrogen receptor modulators (SERMs) to define this class of drug [13-15]. ER activity can also be modulated through indirect activation of the ER by growth factors or cytokines independently of the binding of natural or synthetic hormones [16, 17].

Another way for ERs to regulate gene expression involves protein-protein interactions with transcription factors acting in other transcriptional pathways. Such functional protein-protein interactions of ER have been described with transcription factors c-Jun [18-20], NFκB [21, 22], and Sp1 [23, 24]. These interactions are modulated by receptor and ligand types. For example, differences between interactions of ERα and ERβ were found in the modulation of gene expression through AP1 sites since estradiol activated transcription only through ERα [19].

Finally, estrogens also have very rapid effects outside the nucleus, so-called nongenomic effects [25]. For example, activities associated with protein-protein interactions between ERα and membrane-related enzymes, normally activated by growth factors such as Src-PI3K-Akt or Src-Ras-ERK pathways, have been demonstrated [26, 27].

It has been proposed that ERβ, the more recently discovered type, acts as a dominant regulator of estrogen signaling probably due to the formation of heterodimeric complexes [28]. The responses of ERα and ERβ to agonists and antagonists differ according to inherent differences in the C-terminal ligand-binding domains of the receptors, whereas the magnitude of transcriptional activity is mainly influenced by AF-1 for ERα, but not for ERβ [29].
To study the roles of each receptor in vivo, a series of mice were generated lacking either a functional ERα or ERβ or both [5-7]. These mice have been useful in defining the tissue specificities, localization, and functions of each of the estrogen receptors. ERα and ERβ appear to play important, distinct and non-overlapping roles in the hypothalamus-preoptic area, the pituitary, the cardiovascular system and the gonads. These mouse models also show great promise for use in defining the effectiveness of putative therapeutic antiestrogens.

This review will summarize the expression of ERs in mammary tissues; their roles in the different steps of mammary carcinogenesis, particularly tumor growth and invasion; and the clinical consequences in cancer therapy and prevention.

2. Expression of estrogen receptors in normal, premalignant and malignant mammary tissues

2.1. Normal mammary gland and premalignant lesions

Estrogen and progesterone receptors are essential for mammary gland morphogenesis and physiological events such as puberty and pregnancy. Analysis of estrogen receptor proteins in rat mammary gland have shown that both ERs are expressed, and the results from ERα-KO and ERβ-KO mice reveal that ERα is necessary for mammary gland development. It has been suggested that ERβ co-expression with ERα represses ERα function and may contribute to the insensitivity of the mammary gland to estrogens during lactation [30]. However, in these studies no direct relationship between the presence of these receptors in mammary cells and estrogen-mediated proliferation was obtained by immunohistochemistry [31].

In humans, the major role of estrogens in normal pre- and postpubertal breast development has been evidenced by estrogen therapy of aromatase-deficient female patients [32]. The expression of the two subtypes of ER has been studied in surgical specimens from normal and premalignant tissues [33-36]. Ductal hyperplasia, atypical ductal hyperplasia, and ductal carcinoma in situ (DCIS) are risk factors for invasive breast cancer [37]. The genetic changes involved in the early development of these lesions and their progression to malignant or invasive disease are less defined for breast cancer than for other cancers. Most of the genes involved in mammary carcinogenesis are unknown, with the exception of the BrCa1 and BrCa2 genes in hereditary breast cancers (38). However, the analysis of genetic changes in premalignant lesions compared to adjacent invasive breast cancer supported the hypothesis that the putative precursors and the cancers are genetically related [39].

The expression of ERα and more recently ERβ were studied by immunohistochemistry in normal and premalignant tissues. The percentage of ERα-positive cells is generally low (10–20%) in normal resting mammary glands [33-36] and increases in proliferative benign disease, particularly when associated with atypia [34], and in low-grade DCIS. This has suggested that an elevated receptivity to estrogens in these tissues is involved in their higher risk of tumorigenesis [40]. In contrast to ERα, the ERβ level decreased from proliferative ductal hyperplasia to DCIS, whereas in high-grade DCIS, both ER levels were low or absent [36]. Larger studies are required to determine whether the assays of the two ERs may be predictive of risk in premalignant lesions.
2.2. Invasive breast carcinoma: ERs as prognostic markers of primary breast cancers

2.2.1. ERα is associated with a favorable prognosis in primary breast cancers

Estrogen and progesterone receptors (ERα and PR) have now been studied in clinical breast cancer for more than 20 years. ERα are found in 50-80% of breast tumors and ERα status is essential in making decisions about endocrine therapy [2, 40]. Positive receptor status correlates with favorable prognostic features, including a lower rate of cell proliferation and histologic evidence of tumor differentiation. During the first several years after diagnosis, patients with ER-positive tumors tend to have a lower recurrence rate; however, this is balanced by a higher recurrence rate in subsequent years so that the overall prognostic significance of receptor status is modest. ERα and PR have their greatest utility in predicting response to hormonal therapy, both in the adjuvant setting and for advanced disease. Tumors that express both ERα and PR have the greatest benefit from hormonal therapy, but those containing only ERα or PR still have significant responses [41].

Does the ER-negative tumor derive from ER-positive tumor or is it a totally different disease [42]? This question remains open since differences in ERα expression appear in tumors as early as carcinoma in situ [34] and the gene expression is substantially different in the two types of invasive carcinoma [43, 44]. Moreover, ERα re-expression in an ERα-negative cancer cell is not sufficient to restore the ERα-positive phenotype, particularly in terms of mitogenic response and the pattern of gene expression [45, 46].

2.2.2. Expression of estrogen receptor β

The second receptor, ERβ, has likewise been detected in human breast cancers and may also contribute to hormonal sensitivity and resistance [47-49]. The clinical assay of this receptor has not been performed in large series. The initial studies by reverse transcription PCR analysis concerning the prognostic significance of ERβ were controversial. However, several studies indicated that the ERβ RNA level was decreased in invasive breast cancer tissues compared with the adjacent normal mammary gland [49]. The mechanism and role of the decrease in ERβ in carcinogenesis are unknown. However, these results are consistent with data from ER-KO mice, indicating a stimulatory role of ERα and an inhibitory effect of ERβ in the proliferation of different estrogen-target tissues [5-7]. Initial assays by immunohistochemistry in primary breast cancers indicate that ERβ is not a surrogate for ERα and, as thus may have its own clinical relevance in prognosis and tumor progression [50, 51].

2.2.3. Expression of receptor splicing variants

Numerous studies have identified variant ERα mRNAs in both neoplastic breast tissue and cell lines [reviewed in 52-53]. These mRNA variants lack one or several exons and are usually coexpressed with the wild-type ERα message. Although the existence of ERα variant proteins was initially
controversial, there is now considerable evidence for their expression in normal and neoplastic tissues. Differences in ERα levels measured with an amino-terminal antibody as compared with a carboxy-terminal one [54] suggested the expression of several types of truncated ERα mRNA splice variants lacking one or more exons. Using several antibodies, the endogeneous proteins encoded by the ERα Δ3 (second zinc finger deleted) [55], and ERα Δ5 (hormone binding domain altered) [52, 56] were detected in breast cancer tumors and those encoded by ERα Δ4 (hormone binding domain altered) were detected in ovarian tumors [57]. When expressed individually in cell lines, these variants are shown to modulate the activity of the intact receptor on ERE response, but also have intrinsic activity.

Since the discovery of ERβ, several groups have reported the cloning of differently sized ERβ isoforms [6, 58-61], some with extended N-termini and others with truncation or insertion in the C-terminal ligand-binding domain. It is not known if all these receptor forms exist in tissue but they could have a significant role if heterodimerization occurs with the wild-type receptor. The clinical relevance of these variants in the prognosis of primary breast cancer is not known.

3. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion

3.1. Estrogens increased ER-positive breast cancer cell growth

3.1.1. Direct evidences of the mitogenic effect of estrogens

Estrogens have repeatedly been shown to stimulate the growth of breast cancers since the initial works of Beatson [62] and Lacassagne [63]. The mechanism underlying this effect was specified when ER-positive breast cancer cell lines became available. Estrogens directly increased the growth of breast cancer cells in culture by increasing the number of G0/G1 cells entering into the cell cycle [64, 65]. Antiestrogens are competitive inhibitors of endogenous estrogens and inhibit the mitogenic activity of estrogens in breast cancer. On a molecular basis, they trigger inactive conformation of the ERα, which is then unable to activate transcription via activating function AF2 [9-11, 15-17]. It should be noted that some partial agonist/antagonists such as tamoxifen present an agonist activity on some tissues, such as the uterus, probably through activation of the AF1 function of the ERα [66]. In this way, tamoxifen activates the transcription of genes preferentially controlled by AF1.

These initial data obtained in cell lines or animal tissues were largely confirmed by clinical studies developed with this compound in the last decades. Tamoxifen appears to be an antagonist in the breast and a partial agonist in uterus and bone.

3.1.2. Involved mechanisms?

The mechanism underlying the mitogenic action of estrogens has been widely studied in cell lines and probably results from the complex modulation by the ERs of different transcriptional pathways—thus
involving the regulation of a multitude of genes. The initial and current hypothesis is that estrogens control the growth of primary breast cancers by inducing estrogen-regulated proteins that function as autocrine, paracrine or intracrine growth factors [65]. Estrogens activate (and antiestrogens block) genes controlled by estrogen-responsive elements (EREs). In addition to these classical transcriptional effects, these ligands can also modulate other genes, not containing ERE, via direct protein-protein interaction of ER with other transcription factors. For example, ERα interferes with AP1-directed gene activity [20-22] through a protein-protein interaction with c-Jun. In cell cultures, genes such as cyclin D1 are stimulated by estrogens through an AP-1 pathway and repressed by tamoxifen [67]. By contrast, the non-genomic effects of estrogens on signal transduction do not appear implicated in their mitogenic action, since all key events in cell cycle stimulation can occur in the presence of a MAP kinase-activating inhibitor [68].

The genes responsible for the mitogenic effect of estrogens have not been definitively determined but they probably include secreted growth factors [65], growth factor receptors [69, 70], proteases such as cathepsin D [71] and cyclin/cdk factors [67]. The implication of molecules interfering with the cytoskeleton, such as E-cadherin, a mediator of cell-cell interactions, as been also suggested [72]. E-cadherin is down-regulated by estrogens in normal and tumorigenic breast epithelial cells [73, 74]. Moreover, most of these estrogen-regulated proteins are differentially expressed in ER-positive and ER-negative tumors [43] and this probably contributes to their different metastatic potentials. Actual molecular profiling of breast tumors based on new screening technologies would complete the set of genes associated with different phenotypes [75].

3.2. Are anti-invasive effects mediated by estrogen receptors responsible for their association with a favorable prognosis of breast cancers?

3.2.1. Clinical data supporting the hypothesis that estrogens prevent invasion

There is a great deal of evidence to support the hypothesis that estrogens are important because they are potent mitogens for normal breast epithelial cells, and it is believed that the duration of breast epithelium exposure to estrogens is a significant risk factor for breast cancer development. However, in mammary carcinogenesis, even though the mitogenic effect of estrogens is well demonstrated, the presence of ERα is associated with more differentiated and less invasive tumors and a more favorable prognosis.

Moreover, there is some clinical evidence indicating that estrogens and their receptors protect against invasion. Epidemiological studies have evaluated the breast cancer risk in women using hormone replacement therapy (HRT) where 80% were taking preparations containing estrogen alone [76, 77]. Among the women using HRT, the risk of breast cancer slightly increased, but the tumors under estradiol treatment were confined to localized disease with more favorable prognosis. Tumors in HRT-users were less invasive to axillary lymph nodes and to more distant sites. Other studies of tamoxifen therapy of primary breast cancer suggest that tamoxifen increased the spreading of ERα-positive primary tumor cells to contralateral sites. Tamoxifen use decreased (0.8 fold) the risk of ERα-positive
contralateral breast tumors, but it appeared to increase (4.9-fold) the risk of ERα-negative contralateral tumors [78]. All together, these clinical data are in agreement with an anti-invasive effect of estrogens. These observations have also been confirmed by data from several laboratories, including ours, bringing in vitro evidence of the anti-invasive effects mediated by estrogen receptors. In human breast cancer cell lines, ERα expression was associated with low invasiveness and low motility in culture tests [44, 79]. Moreover, when ERα-positive cells were implanted in nude mice, tumors appeared only in the presence of estrogens and are poorly metastatic as compared to those developed from ERα-negative breast cancer cell lines [80]. The protective role of ERs against tumor invasion and metastasis was further studied by analyzing the effect of estradiol and ERs on cancer cell motility and invasiveness in different breast cancer cell lines.

3.2.2. Estrogen receptors inhibit invasion through two distinct mechanisms in the presence or absence of hormone

3.2.2.1 Estrogens inhibit invasion via ERE-regulated genes

The effects of estrogens on cell invasiveness have been studied in vitro using a two-chamber culture model and Matrigel, a reconstituted basement membrane. The initial studies indicated that the invasiveness of MCF7 breast cancer cells was increased by antiestrogens [81, 82]. More recent studies have demonstrated that estradiol significantly reduces invasiveness and that this inhibition is reversed by antiestrogens [83-87]. This conclusion was noted in several ERα-positive cancer cell lines established from breast [83] or ovary [85], and in different ERα-negative cancer cells constitutively expressing ERα after stable transfection [45, 84, 87]. Similar results were also obtained on the migration of normal cells from vascular smooth muscle [86]. These in vitro data were confirmed in nude mice, since the formation of experimental lung metastases from metastatic ERα-negative MDA-MB-231 breast cancer cells was inhibited by estradiol after ERα expression by transfection [45, 87]. In contrast to the effects of estradiol on growth, which are opposite in native ER-positive cells (stimulation) and ER-transfected cells (repression), it should be noted that this hormone induces the same anti-invasive effect in both cell types. This suggests that different pathways control cell proliferation and cell invasion.

The mechanism by which estradiol inhibits invasion was studied using a new invasion assay based on the transient expression of ERα in the ERα-negative MDA-MB-231 cell line [88, 89]. Estradiol treatment decreased by 2-fold the invasiveness in ERα transfectant (Figure 2). The inhibitory effect of estradiol is reversed by both types of antiestrogens, OH-tamoxifen (4-hydroxytamoxifen, the active metabolite of tamoxifen) and ICI 164,384, a pure antiestrogen. By contrast, estradiol or antiestrogen treatments did not significantly affect invasion of control ER-negative cells. Moreover, the analysis of different ERα deletion mutants strongly suggested that some estrogen-regulated genes negatively control invasion since the integrity of the hormone-binding domain, the DNA-binding domain and
activating function 2 (AF2) of ERα was required [89]. In contrast, the N-terminal domain containing the AF1 function is not involved since a deletion ΔAB mutant was as efficient as the wild-type receptor. As possible candidates among estrogen-regulated proteins, those that increase cell-cell adhesion, such as E-cadherin, or that decrease matrix degradation, such as α1-antichymotrypsin, should be considered [reviewed in 83, 90].

3.2.2.2 Estrogen receptors inhibit invasion independently of ligand binding: involvement of protein-protein interactions

Using the transfection/invasion method described above, we also demonstrated that expression of unliganded ERα and several mutants deleted in the hormone-binding domain drastically reduced MDA-MB-231 cell invasiveness in Matrigel tests. As shown in Figure 2, in estrogen-deprived conditions, transient wild type ERα expression induced a 3-fold decrease in the invasiveness of transfected cells and estradiol treatment reinforced the ligand independent effect by an additional 2-fold reduction. The strong inhibition due to the unliganded ERα is reversed by the pure antiestrogen ICI 164,384 which is known to decrease receptor concentration but not by OH-tamoxifen. In breast cancer cells, OH-tamoxifen and other tamoxifen derivatives were shown to up-regulate the receptor by decreasing its degradation (91). This increase of ERα concentration could explain the anti-invasive properties of tamoxifen in certain models in vitro (92) and could participate to its beneficial effects in vivo.

The domain involved in ligand-independent inhibition of invasion has been further characterized by progressive deletions in the ERα sequence. As shown in Figure 3, the first zinc finger of the DNA-binding domain (i.e., amino acids 179-215) is responsible for the anti-invasive activity. This activity is independent of the two key aminoacids which are essential for ERE binding and the estrogen specificity of the responses [93]. Among the different nuclear receptors, invasion was specifically decreased by the expression of ERα (3-fold) and to a lesser extent by ERβ (2-fold), but was not affected by thyroid hormone receptor α1, vitamin D receptor, retinoid acid receptor α, or glucocorticoid and androgen receptors. On the basis of these data, it was proposed that unliganded ER decreases invasiveness via interaction of the first zinc finger region with an unknown nuclear factor. Moreover, immunocytochemical studies of ERα-positive breast cancer cell lines (MCF7, ZR75.1, T47D) indicated that in hormone-deprived conditions, ERα expression was inversely correlated with cell motility [89]. Migrating cells had lower ER levels than non-migrating cells. Finally, treatments such as phorbol ester or pure antiestrogen, known to decrease ERα levels in MCF7 breast cancer cells, significantly increased in vitro invasiveness [79, 89]. Taken together, these in vitro data indicate a protective role of ERα against the invasiveness of breast cancer cells.

These data obtained on cell cultures cannot be extrapolated to the in vivo situation, where the endocrine and paracrine effects of estrogens may have major consequences on the invasiveness of cancer cells. However, their possible implications in the monitoring of breast cancer should be discussed. Particularly, negative effects should be anticipated in the clinical use of pure antiestrogens such as ICI 164,384 or ICI 182,780, since these drugs increased in vitro cancer cell invasiveness by
inhibiting the protective effect of both estrogens and ER\textsubscript{\alpha} by decreasing its content. ER\textsubscript{\alpha} expression should perhaps also be preserved in cancer cells during adjuvant therapies in order to maintain differentiation and a low invasive potential. In addition, these results suggest new therapeutic strategies based on ER\textsubscript{\alpha} re-expression to prevent the proliferation, invasiveness and metastatic potency of ER\textsubscript{\alpha}-negative breast cancer cells [90].

3.3. Role of estrogen receptor variants in cancer progression?

3.3.1. Splicing variants of ER alpha and beta

Numerous studies have identified variant ER\textsubscript{\alpha} and ER\textsubscript{\beta} mRNAs in both neoplastic breast tissue and cell lines [52, 53]. These mRNA variants lack one or several exons and are usually coexpressed with the wild-type ER message. However, the pathophysiological significance of ER\textsubscript{\alpha} variant expression is unclear. Several studies using transient transfection have shown that individual ER\textsubscript{\alpha} variant proteins can have positive or negative effects on the wild-type ER\textsubscript{\alpha} activity [52, 53]. The efficacy of these variants depends on their relative levels as compared to the wild-type protein, and a 10-20-fold excess might be necessary for significant activity [55]. The presence of one or more variant proteins in variable levels in normal breast epithelium and neoplastic tissue could influence the wild-type receptor, but it has not yet been demonstrated that these variants are involved in estrogen-independent growth or antiestrogen resistance. The variants ER \Delta 3 (lacking the second zinc finger) and ER \Delta 4 (deleted in the hormone-binding domain) are overexpressed in normal cells but not in breast cancer cells. These variants, which contain the first zinc finger domain, could have an invasion-suppression activity independent of the hormone action. This was verified by expression of the ER \Delta 3 variant [55]. A more detailed clinical evaluation of the ER\textsubscript{\alpha} and ER\textsubscript{\beta} variants is required to determine their influence in the different steps of mammary carcinogenesis and the response to therapy.

3.3.2. Mutants with point mutation

It has been estimated that only 1 % of primary breast tumors contain missense mutations of the ER\textsubscript{\alpha} gene [94]. These mutations may be more frequent in metastatic breast lesions and could affect normal ER\textsubscript{\alpha} function. Unfortunately, functional studies with most ERs containing missense mutations have not yet been reported. Studies performed with the Tyr537Asn indicate that this mutant exhibited a potent, hormone-independent transcriptional activity probably due to a conformational change in the receptor molecule that mimics hormone binding [95]. A hypersensitive ER mutant Lys303Arg has been found in premalignant breast lesions, suggesting a role in early carcinogenesis [96]. This suggests that these somatic mutations, although infrequent, may significantly alter the evolution of individual tumors.

4. Antiestrogen approaches for breast cancer therapy and prevention

4.1. Tamoxifen and other adjuvant therapies of breast cancer
The antiestrogen tamoxifen has been in use for more than two decades to treat hormone-dependent breast cancers [97-99]. Its undeniable value has been demonstrated in two settings. In the first, tamoxifen is used as a systemic adjuvant therapy after surgery for early breast cancer, where, after 5 years of treatment, it reduces disease recurrence and improves survival regardless of patient age and nodal status [98]. Second, in patients with metastatic disease who have ER-positive tumors, tamoxifen is effective in approximately 50% of the cases [2, 3, 40, 100].

In adjuvant therapy, the benefit of 5 years of tamoxifen has been evidenced in the presence and absence of chemotherapy in terms of the frequency of relapse and survival. More prolonged tamoxifen therapy has no additional advantage through 4 years of follow-up. However, the addition of tamoxifen to chemotherapy in patients with estrogen receptor-negative tumors resulted in no significant advantage over that achieved from chemotherapy alone [100]. This verifies the concept that tamoxifen treatment is a mechanism-based therapy of functional estrogen receptors. The promising use for tamoxifen for ductal carcinoma in situ or breast cancer prevention has also been noted in certain patient groups [101].

Alternatives to tamoxifen therapy include the use of new SERMs and aromatase inhibitors. The ideal SERM would fully block ERs in the breast cancer tumor but would not cross the blood-brain barrier and thus would not stimulate hot flashes by blocking the effects of estrogens in the brain, nor would it stimulate endometrial proliferation. In addition, this agent would have no harmful effects on blood lipids or bone density. The search for this ideal SERM has led to the development of pure antagonists that exhibit no agonist activity in any tissue yet measured. The first pure ER antagonist, ICI 164,384, was described by Wakeling and Bowler [102] and this was followed by fulvestrant (Flaxodel™, ICI 182,780) with increased antiestrogenic activity. Fulvestrant was formulated by adding a long-chain alkyl moiety at the 7-alpha position of 17-beta-estradiol (Figure 4). It is devoid of estrogen agonist activity in a large number of in vitro and in vivo preclinical models. In animal models, it does not cross the blood-brain barrier and appears to be neutral with respect to lipids and bone. Fulvestrant down-regulates the estrogen receptor and is active in tamoxifen-resistant breast cancer cell lines. Clinical studies have demonstrated that this agent is active in second-line therapy after tamoxifen failure [103] but as yet it has been shown no efficacy and limited safety in pre-menopausal women. Other SERMs are in development, with the goal of reducing toxicity and/or improving efficacy as compared to tamoxifen.

In premenopausal women, alternatives to tamoxifen include ovarian suppression with luteinizing hormone-releasing hormone (LHRH) agonists, ovarian ablation and progestins. A recent study involving patients with metastatic disease indicated a higher survival with the combination of tamoxifen and ovarian suppression versus tamoxifen alone [100]. The efficacy of new aromatase inhibitors in premenopausal women has not been established but the first-line generation agent aminoglutethimide was not effective. The recent studies indicating that progestin associated to estrogen increases breast cancer incidence and mortality in HRT users [104, 105] also raises questions about the use of progestin in breast cancer therapy of premenopausal women.

Randomized trials are needed to define the optimal sequencing of the available endocrine agents such as nonsteroidal aromatase inhibitors and tamoxifen in postmenopausal women and to compare
alternative regimens of tamoxifen combined with ovarian ablation or LHRH analogue in premenopausal women.

4.2. Aromatase inhibitors

New adjuvant strategies include the use of aromatase inhibitors in place of, or in addition to, tamoxifen, and the use of adjuvant bisphosphonates. The third generation of inhibitors include the steroidal drug exemestane and the nonsteroidal drugs letrozole and anastrozole. These very potent inhibitors of aromatase decrease estrogen levels below the level of detection of most clinical assays. All three agents have been found to be equivalent or superior to megestrol acetate as a second line therapy for metastatic breast cancer. In the first line setting, anastrozole and letrozole, are now considered more effective than tamoxifen as first-line therapy for metastatic breast cancer in postmenopausal women, regardless of whether the patients have received tamoxifen as adjuvant therapy [103, 106]. These aromatase inhibitors are less associated than tamoxifen with serious side effects, such as endometrial cancers and thromboembolic complications [107]. Letrozole is more effective as a neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive and ER-positive primary breast cancer [108]. This suggests that the growth-promoting effects of these receptor tyrosine kinases are estrogen-dependent.

The mechanisms of ER signaling inhibition by tamoxifen and aromatase inhibitors probably differ on multiple aspects since these two classes of drugs alter differently the conformation of the estrogen receptors and consequently the nature of the interacting cofactors. The types of tumor resistance induced by these treatments are different as evidenced by the efficacy of aromatase inhibitors on tamoxifen-resistant tumors. However, the use of aromatase inhibitors is at the expense of accelerated bone loss, and strategies to minimize this side effect are under investigation [107]. Adjuvant bisphosphonates have been found to reduce the bone loss associated with cancer treatments and their efficacy is now being evaluated in adjuvant trials in early breast cancer [109]. Whether or not the higher efficacy of aromatase inhibitors over SERMs is confirmed in postmenopausal women, it would be interesting to study their effects on ERα expression, as well as the potential role of adrenal androgens such as 5-androstenediol, which have an affinity for ERα similar to that of tamoxifen [110, 111].

4.3. Second therapy for antiestrogen resistant tumors

A significant proportion of ER-positive tumors are resistant to tamoxifen therapy either at the first treatment or after an initial positive response [112]. Other SERMs, such as triphenylethylene derivatives of tamoxifen (Toremifene, Idoxifene) and benzothiophenes like raloxifene, were cross-resistant with tamoxifen, which implied that neither would be effective as second-line therapy [98, 99]. The pure antiestrogens have been developed to prevent the growth of tamoxifen-resistant tumors. Fulvestrant was the first pure antagonist tested in tamoxifen-resistant breast carcinoma. Phase III trials have been conducted comparing fulvestrant with the aromatase inhibitor, anastrozole, in
postmenopausal patients with advanced breast cancer progressing after prior endocrine therapy. Objective response and median response duration were similar in fulvestrant-treated and anastrozole-treated patients [112]. New non-steroidal antiestrogens, EM 800 and its active derivative EM-652, are also pure antagonists with a higher affinity for ER than fulvestrant or estradiol. These compounds are under evaluation in preclinical models [113].

The cross-talk of estrogen receptors with growth factor signalling pathway is well demonstrated and appears implicated in breast cancer progression and tamoxifen resistance. Overexpression of growth factor receptor causes resistance to tamoxifen through protein kinase activation. Moreover, preclinical studies indicated that inhibitors of growth factor tyrosine kinase have the potential to delay or even reverse tamoxifen resistance (98). Clinical trials combining kinase inhibitors and endocrine therapies should afford a possibility to modulate simultaneously two different pathways implicated in cancer progression.

4. Implication of estrogens in breast cancer carcinogenesis and use of antiestrogens as cancer chemopreventive agents

Estrogens may increase breast cancer risk by acting at different steps of mammary carcinogenesis [4]: as a pre-initiator when the exposure occurs during fetal life, as an initiator by inducing DNA damage through formation of free radicals, or as a mitogen by stimulating the growth of existing malignant cells.

4.4.1. Tamoxifen, the first chemopreventive SERM in high-risk pre- and postmenopausal women

The extensive use of the long-term adjuvant tamoxifen has revealed that this selective estrogen receptor modulator (SERM) produces antiestrogenic actions in the breast but estrogen-like actions in bone, and lowers serum cholesterol. These properties not only allowed the application of tamoxifen but also the development of raloxifene to prevent osteoporosis with the potential to prevent breast cancer in postmenopausal women.

In a North American breast cancer prevention trial, tamoxifen reduced the incidence of ER-positive breast cancer among all women by 62% [114]. A similar reduction was found among healthy BrCa2 carriers [115]. In contrast, tamoxifen use beginning at age 35 years or older did not reduce breast cancer incidence among healthy women with inherited BrCa1 mutations [115].

4.4.2. Raloxifene and tamoxifen comparison

Raloxifene is a second-generation SERM that has estrogenic effects on bone and lipid metabolism, and antiestrogenic effects on breast tissue. Unlike tamoxifen, raloxifene displays antiestrogenic effects on the endometrium and may serve as a safer alternative to tamoxifen in prevention [116]. A randomized placebo-controlled trial with 3 years of raloxifene treatment was conducted to demonstrate that this
SERM efficiently prevents osteoporosis in postmenopausal women. As a secondary end point, this trial also showed that raloxifene reduces the risk of both in situ and invasive breast cancer by 65%. The risk of developing estrogen receptor (ER)-positive cancers was significantly decreased by 10-fold. Raloxifene was shown to reduce breast cancer risk regardless of lifetime estrogen exposure, but the reduction was greater in those with higher lifetime exposure to estrogens [117]. Whether this benefit is due to a decrease in carcinogenesis or to lower tumor growth will be specified in the next few years. Finally, the comparison of tamoxifen and raloxifene in breast cancer prevention has now been initiated by enrolling cancer-free but high-risk postmenopausal women [118].

In addition to raloxifene, other classes of chemopreventive agents are being studied. Future directions include combined therapies by the addition of an aromatase inhibitor to a SERM.

5. Conclusions

Experimental and clinical data have demonstrated the importance of ER in the development and progression of breast cancer and this has led to its becoming a major target for breast cancer treatment. The efficacy of antiestrogen treatment to inhibit (and probably prevent) the growth of ER-positive breast cancer cells has been extensively documented. However, ER status is generally associated with more differentiated and less invasive tumors, suggesting that it may have a protective role against metastatic progression. The exact role of ER expression in the differences observed between ER-positive and ER-negative tumors, such as gene expression and genomic mutations, remains unknown. Estrogens and their receptors probably have a complex action in breast cancer cells. We present here a dual role as mitogen and anti-invasive agent, but estrogens likely affect other steps involved in cancer progression, such as angiogenesis [119] and immune response [120]. Estrogens inhibit invasiveness via a classical activation of ERE-regulated genes, whereas the unliganded receptor acts through interaction with an unknown protein. Non-classical mechanisms of action, in which the receptor may bind to other transcription factors instead of DNA or to the proteins involved in pathways such as motility and invasion, are now being investigated. The identification of the factors that inhibit the invasiveness of ERα-positive cells would be a useful step in the development of new therapeutic targets to cure the most aggressive ERα-negative tumors.

References


[70] Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Seminars Oncol 1999;26:89-95.


Vitae

Platet: Nadine Platet, Ph.D. in 1998, is a Research Engineer at the National Institute for Health and Medical Research (INSERM), Laboratory of Preclinical Neurosciences, Unit 318, Grenoble, France.

Cathiard: Anne-Marie Cathiard, Ph.D. in 1981, is a Study Engineer at the National Institute for Health and Medical Research (INSERM), Laboratory of Molecular and Cellular Endocrinology of Cancers, Unit 540, Montpellier, France. She has had a long-standing involvement in research on steroid hormone action and endocrinology.

Gleizes: Michel Gleizes is a laboratory technician at the University of Montpellier, France, with experience in immunohistochemistry, protein biochemistry and cell biology.
Garcia: Marcel Garcia, Ph.D. in 1981, is a Director of Research at the National Institute for Health and Medical Research (INSERM), Laboratory of Molecular and Cellular Endocrinology of Cancers, Unit 540, Montpellier, France. His current research interest is hormone dependency and the metastatic progression of breast and ovarian cancers. Specifically, his investigations focus on target genes such as cathepsin D and estrogen receptors for therapeutic applications. He has published over 130 scientific papers and chapters in the fields of endocrinology and oncology.
Figure 1: Structures and functions of estrogen receptors
The human estrogen receptors ERα and ERβ contain five functional domains (A to E) as other members of the nuclear receptor superfamily and an additional domain F in their C terminal part [8-16]. The binding of estrogen in the hormone binding domain (HBD) induces a trans conformational change of the whole molecule allowing unmasking of the activating function 1 (AF1) in domain A/B by removal of chaperone (HSP90), dimerization, activation of activating function 2 (AF2) in the C-terminal part of the E domain and binding to estrogen-responsive element (ERE) on DNA via domain C.
Figure 2: Effect of ERα expression and estradiol treatment on MDA-MB-231 cell invasion.

ERα-negative MDA-MB-231 cells were transiently cotransfected with ERα-expressing vector (HEGO) or control vector (pSG1), and a luciferase expressing vector used as a marker of transfected cells [88]. The percentage of cells invading Matrigel was estimated in the presence of 20 nM estradiol (E2), 100 nM 4-hydroxy-tamoxifen (OHT), 100 nM ICI 164,384 (ICI) or ethanol alone (C). * p<0.01 versus pSG1 control; • p<0.05 versus HEGO control. Reproduced from [89, copyright 2000, Endocrine Society].
Figure 3: E2-independent inhibition of cancer cell invasion by ERα requires the first zinc finger region.

Effects of ERα mutants on MDA-MB-231 breast cancer cell invasiveness were determined in transfection/invasion assay. + for active mutant, 0 for inactive mutant. NLS = nuclear localization signal. Reproduced from [89, copyright 2000, Endocrine Society].
Figure 4: Structure of estradiol and major SERM used in therapy.